The Trump administration’s April 2026 executive actions have accelerated federal cannabis policy, with the Department of Justice and DEA immediately moving FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. This step followed a December 2025 executive order directing expedited review and directly shapes trader focus on whether broader rescheduling of all marijuana to Schedule III occurs via the administrative hearing scheduled to begin June 29, 2026. Congressional appropriations measures seeking to limit further agency action add procedural uncertainty, while historical patterns of DEA rulemaking timelines and Senate confirmation dynamics inform assessments of completion by year-end. These verified developments anchor current market positioning on the pace of administrative and legislative progress.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui$758,923 Vol.
June 30
2%
December 31
24%
$758,923 Vol.
June 30
2%
December 31
24%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Pasar Dibuka: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The Trump administration’s April 2026 executive actions have accelerated federal cannabis policy, with the Department of Justice and DEA immediately moving FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. This step followed a December 2025 executive order directing expedited review and directly shapes trader focus on whether broader rescheduling of all marijuana to Schedule III occurs via the administrative hearing scheduled to begin June 29, 2026. Congressional appropriations measures seeking to limit further agency action add procedural uncertainty, while historical patterns of DEA rulemaking timelines and Senate confirmation dynamics inform assessments of completion by year-end. These verified developments anchor current market positioning on the pace of administrative and legislative progress.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan